Sequencing of BRAF inhibitors and ipilimumab in patients with metastatic melanoma: a possible algorithm for clinical use.
about
New developments in the management of advanced melanoma - role of pembrolizumabIpilimumab, vemurafenib, dabrafenib, and trametinib: synergistic competitors in the clinical management of BRAF mutant malignant melanomaEmerging targeted therapies for melanoma treatment (review)The Evolving Role of Immune Checkpoint Inhibitors in Cancer TreatmentActivated Ras as a Therapeutic Target: Constraints on Directly Targeting Ras Isoforms and Wild-Type versus Mutated ProteinsUpdate on benefit of immunotherapy and targeted therapy in melanoma: the changing landscape.Sequential treatment with ipilimumab and BRAF inhibitors in patients with metastatic melanoma: data from the Italian cohort of the ipilimumab expanded access program.Efficacy and safety of ipilimumab in patients with advanced melanoma and brain metastasesMelanoma: more answers, more questionsAntibody therapies for melanoma: new and emerging opportunities to activate immunity (Review).BRAFV600E-mutant melanoma presenting with cardiac involvement.Clinical utility of a blood-based BRAF(V600E) mutation assay in melanomaIpilimumab for advanced melanoma: experience from the Spanish Expanded Access Program.Efficacy of PARP Inhibitor Rucaparib in Orthotopic Glioblastoma Xenografts Is Limited by Ineffective Drug Penetration into the Central Nervous System.Deltex-3-like (DTX3L) stimulates metastasis of melanoma through FAK/PI3K/AKT but not MEK/ERK pathway.Acquired BRAF inhibitor resistance: A multicenter meta-analysis of the spectrum and frequencies, clinical behaviour, and phenotypic associations of resistance mechanisms.Genetics of melanomaInnovative therapeutic strategies in the treatment of brain metastases.The MAPK (ERK) Pathway: Investigational Combinations for the Treatment Of BRAF-Mutated Metastatic Melanoma.Prolonged Benefit from Ipilimumab Correlates with Improved Outcomes from Subsequent Pembrolizumab.Inter- and intra-patient heterogeneity of response and progression to targeted therapy in metastatic melanoma.Metastasis in central nervous system: Clinicopathological study with review of literature in a tertiary care center in South India.Severe cutaneous and neurologic toxicity in melanoma patients during vemurafenib administration following anti-PD-1 therapy.Vemurafenib for the treatment of melanoma.Novel targets in the treatment of advanced melanoma: new first-line treatment options.Treatment of BRAF-mutant melanoma: the role of vemurafenib and other therapies.The intersection of immune-directed and molecularly targeted therapy in advanced melanoma: where we have been, are, and will be.Biology in prevention and treatment of brain metastases.Major therapeutic developments and current challenges in advanced melanoma.Treating advanced melanoma: current insights and opportunities.Translational research in oncology--10 years of progress and future prospects.Blinded by the light: why the treatment of metastatic melanoma has created a new paradigm for the management of cancer.Correlation between previous treatment with BRAF inhibitors and clinical response to pembrolizumab in patients with advanced melanoma.Combination Treatment of Patients with BRAF-Mutant Melanoma: A New Standard of Care.Targeting protein kinase-b3 (akt3) signaling in melanoma.What have we learned from cancer immunotherapy in the last 3 years?Comparative mutational landscape analysis of patient-derived tumour xenografts.Do BRAF inhibitors select for populations with different disease progression kinetics?Harnessing the immune system to provide long-term survival in patients with melanoma and other solid tumors.Lactate dehydrogenase as a selection criterion for ipilimumab treatment in metastatic melanoma.
P2860
Q26781931-8A4E75C2-5B64-4A1D-8EB6-AC9BBFB9EE96Q26824310-9A948486-2477-4BA4-BB8F-40027C61006DQ26829997-C7D14047-AEFD-4011-A511-9829A3B2315CQ27022789-744B9150-B044-4ED1-A781-498E3D5031F0Q27027458-203A9027-12D5-452C-BE17-EDD808888929Q27691824-24321D6E-4721-4467-ABE5-7614856AF2E8Q30746423-3C5356B3-AC31-4E3D-841E-F95D963AEEE2Q33620317-772CC88E-CACB-4456-8243-C945C776E0F5Q33777422-E75F0738-980B-4BF2-97A2-FB8249CACA53Q34000700-BB4EB656-5BD4-47EF-8946-4419FCA163DDQ34276579-DDE4AC79-068F-4B4B-B5D3-316FFB26C8C6Q34646769-AB7F47BE-AC45-4C5A-84B7-006CE44CA7EEQ35688401-260BCCDA-A47A-417D-8C64-38F1E6ACFE85Q35799917-3B2F88DF-A6FD-43F2-951C-0C1AEFA678FEQ35987334-7664EF33-4D7A-40C9-90E6-ED73A430E0F5Q36338753-E26E70B8-DD52-493E-B912-C3F9E9646699Q36563659-534DDBB6-555D-411E-A9B1-5EEA5B70EB35Q36590195-EA444551-4E43-46BE-B245-DCDDEB0FC373Q36771571-61471F8B-635C-48F1-9EA9-3F2CBA217FB0Q37082862-1786C3FB-2561-4125-AD58-195E434F2247Q37439417-81B58091-634F-431E-95D4-4BA10D7F6BA0Q37467246-FC2B51A8-142B-4AF5-A8E4-226C475F7A95Q37527772-C3D9419A-0A6B-4F81-A576-11F99ADA17AFQ38055208-ED5AC20B-008D-42D6-8651-E1B9A44C6BB4Q38095228-36658715-96FC-4B2A-8FB8-50B8C560685EQ38147850-BC8E8A67-6FE2-4C39-A922-A14CD33398FDQ38148745-0BD36EB5-B889-4DBB-B3B6-B9F03A4E3C36Q38156192-BE4A335F-50D4-4059-AF71-42DB408DEAC7Q38180142-F2075AB2-88D8-40B0-AD38-46A489A5A17CQ38250316-CC8F231A-7BFF-4F61-8AC3-85A9A09A8B93Q38257126-F71AF12A-7FA5-47DA-83A9-EAF6842EE28AQ38371675-65D1A274-04FB-4240-8737-F891385C0052Q38839130-E382099D-E177-44F0-ACFB-822A3FA7DEE1Q39069585-0D6936C1-26B7-4F7A-9015-4FFDF142ADA7Q39074281-1CBC4666-4635-43FB-B4FD-95AA421F391BQ40065733-5622EC4E-F2CE-4DBB-A963-B1B3DCAF1D9FQ40366394-CC696F3F-1DE7-468E-9B5C-B6632BC47BB3Q41051660-9C7A3673-8996-4328-9E5C-35003A1B57F8Q42380935-024BD892-C076-46B6-A2F6-B4C5855F8870Q45349601-A7624154-54BE-4D1B-92C1-3775EBEC5C2D
P2860
Sequencing of BRAF inhibitors and ipilimumab in patients with metastatic melanoma: a possible algorithm for clinical use.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年学术文章
@wuu
2012年学术文章
@zh-cn
2012年学术文章
@zh-hans
2012年学术文章
@zh-my
2012年学术文章
@zh-sg
2012年學術文章
@yue
2012年學術文章
@zh
2012年學術文章
@zh-hant
name
Sequencing of BRAF inhibitors ...... le algorithm for clinical use.
@ast
Sequencing of BRAF inhibitors ...... le algorithm for clinical use.
@en
type
label
Sequencing of BRAF inhibitors ...... le algorithm for clinical use.
@ast
Sequencing of BRAF inhibitors ...... le algorithm for clinical use.
@en
prefLabel
Sequencing of BRAF inhibitors ...... le algorithm for clinical use.
@ast
Sequencing of BRAF inhibitors ...... le algorithm for clinical use.
@en
P2093
P2860
P50
P356
P1476
Sequencing of BRAF inhibitors ...... le algorithm for clinical use.
@en
P2093
Anna Romano
Ester Simeone
Nicola Mozzillo
P2860
P2888
P356
10.1186/1479-5876-10-107
P577
2012-05-28T00:00:00Z